These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32152222)

  • 1. Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors.
    Mamoor M; Postow MA; Lavery JA; Baxi SS; Khan N; Mao JJ; Rogak LJ; Sidlow R; Thom B; Wolchok JA; Korenstein D
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls.
    Boekhout AH; Rogiers A; Jozwiak K; Boers-Sonderen MJ; van den Eertwegh AJ; Hospers GA; de Groot JWB; Aarts MJB; Kapiteijn E; Ten Tije AJ; Piersma D; Vreugdenhil G; van der Veldt AA; Suijkerbuijk KPM; Rozeman EA; Neyns B; Janssen KJ; van de Poll-Franse LV; Blank CU
    Acta Oncol; 2021 Jan; 60(1):69-77. PubMed ID: 32924708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab.
    Rogiers A; Leys C; Lauwyck J; Schembri A; Awada G; Schwarze JK; De Cremer J; Theuns P; Maruff P; De Ridder M; Bernheim JL; Neyns B
    J Immunol Res; 2020; 2020():2192480. PubMed ID: 32775464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life in survivors of advanced melanoma treated with anti-PD1-based immune checkpoint inhibitors.
    Looman EL; Cheng PF; Lai-Kwon J; Morgan L; Wakkee M; Dummer R; Dimitriou F
    Cancer Med; 2023 Jun; 12(11):12861-12873. PubMed ID: 37119050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods study.
    Tometich DB; Geiss C; Maconi ML; Chavez M; Hoogland AI; Li X; Nieves-Lopez A; Rodriguez Y; Bryant C; Brohl AS; Eroglu Z; Markowitz J; Tarhini AA; Hwu P; Khushalani NI; Jim HSL
    Support Care Cancer; 2024 May; 32(6):330. PubMed ID: 38709312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Home-based multidimensional survivorship programmes for breast cancer survivors.
    Cheng KKF; Lim YTE; Koh ZM; Tam WWS
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD011152. PubMed ID: 28836379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of the quality of life in Chinese breast cancer survivors.
    Xia J; Tang Z; Deng Q; Yang R; Wang J; Yu J
    Breast Cancer Res Treat; 2018 Jan; 167(2):537-545. PubMed ID: 28965272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study.
    Rogiers A; Leys C; De Cremer J; Awada G; Schembri A; Theuns P; De Ridder M; Neyns B
    Support Care Cancer; 2020 Jul; 28(7):3267-3278. PubMed ID: 31745697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. All's well that ends well? Quality of life and physical symptom clusters in long-term cancer survivors across cancer types.
    Zucca AC; Boyes AW; Linden W; Girgis A
    J Pain Symptom Manage; 2012 Apr; 43(4):720-31. PubMed ID: 22277904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data.
    Almutairi AR; Erstad BL; McBride A; Slack M; Abraham I
    Expert Opin Drug Saf; 2021 Apr; 20(4):489-497. PubMed ID: 33445985
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapy preferences in melanoma treatment-Willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease.
    Weiss J; Kirchberger MC; Heinzerling L
    Cancer Med; 2020 Sep; 9(17):6132-6140. PubMed ID: 32649807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma.
    Ascierto PA; Del Vecchio M; Mackiewicz A; Robert C; Chiarion-Sileni V; Arance A; Lebbé C; Svane IM; McNeil C; Rutkowski P; Loquai C; Mortier L; Hamid O; Bastholt L; Dreno B; Schadendorf D; Garbe C; Nyakas M; Grob JJ; Thomas L; Liszkay G; Smylie M; Hoeller C; Ferraresi V; Grange F; Gutzmer R; Pikiel J; Hosein F; Simsek B; Maio M
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management.
    Huffman BM; Kottschade LA; Kamath PS; Markovic SN
    Am J Clin Oncol; 2018 Aug; 41(8):760-765. PubMed ID: 28749795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy.
    McDowell LJ; Rock K; Xu W; Chan B; Waldron J; Lu L; Ezzat S; Pothier D; Bernstein LJ; So N; Huang SH; Giuliani M; Hope A; O'Sullivan B; Bratman SV; Cho J; Kim J; Jang R; Bayley A; Ringash J
    Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):340-352. PubMed ID: 30191868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
    Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
    Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of quality of life among long-term melanoma survivors and non-melanoma controls: a cross-sectional study.
    Vogel RI; Strayer LG; Engelman L; Nelson HH; Blaes AH; Anderson KE; Lazovich D
    Qual Life Res; 2017 Jul; 26(7):1761-1766. PubMed ID: 28243994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Quality of Life in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma.
    Nies M; Klein Hesselink MS; Huizinga GA; Sulkers E; Brouwers AH; Burgerhof JGM; van Dam EWCM; Havekes B; van den Heuvel-Eibrink MM; Corssmit EPM; Kremer LCM; Netea-Maier RT; van der Pal HJH; Peeters RP; Plukker JTM; Ronckers CM; van Santen HM; Tissing WJE; Links TP; Bocca G
    J Clin Endocrinol Metab; 2017 Apr; 102(4):1218-1226. PubMed ID: 28001468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-state utilities in long-term advanced melanoma survivors comparable with the general population.
    Egeler MD; van de Poll-Franse LV; Tissier R; Rogiers A; Boers-Sonderen MJ; van den Eertwegh AJ; Hospers GA; de Groot JWB; Aarts MJB; Kapiteijn E; Piersma D; Vreugdenhil G; van der Veldt AA; Suijkerbuijk KPM; Neyns B; Janssen KJ; Blank CU; Retèl VP; Boekhout AH
    Qual Life Res; 2023 Sep; 32(9):2517-2525. PubMed ID: 37079262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
    Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS
    Lancet Oncol; 2016 Jul; 17(7):943-955. PubMed ID: 27269740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptom clusters and quality of life in survivors of lung cancer.
    Fox SW; Lyon DE
    Oncol Nurs Forum; 2006 Sep; 33(5):931-6. PubMed ID: 16955121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.